Compare STBA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | URGN |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | United States |
| Employees | 1209 | 291 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1995 | 2016 |
| Metric | STBA | URGN |
|---|---|---|
| Price | $44.22 | $28.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $43.00 | $29.29 |
| AVG Volume (30 Days) | 227.6K | ★ 955.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | $10.20 | $129.09 |
| Revenue Next Year | $4.14 | $70.96 |
| P/E Ratio | $46.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.01 | $3.42 |
| 52 Week High | $45.17 | $32.37 |
| Indicator | STBA | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 62.20 |
| Support Level | $42.25 | $17.86 |
| Resistance Level | $44.89 | $30.00 |
| Average True Range (ATR) | 0.80 | 1.90 |
| MACD | -0.13 | 0.19 |
| Stochastic Oscillator | 53.70 | 62.20 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.